AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 171 min read$NKTR

Zalevsky Jonathan sold $336K of NKTR

Zalevsky Jonathan (Chief R&D Officer) sold 5,538 shares of NEKTAR THERAPEUTICS (NKTR) at $60.71 ($0.34M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zalevsky Jonathan
Published Jun 17, 2026, 11:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NKTR
Neutral
medium confidence
Mentioned
$NKTR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NKTRNeutralLow
01

Why it matters

This adds a fresh datapoint on officer selling activity (5,538 shares) but does not introduce new business fundamentals or catalysts.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a fundamental repricing.

03

What to watch

The article provides only the sale details; it does not include any concurrent insider buys, changes in guidance, or clinical/regulatory updates that would better explain directional risk.

Relevance 3/10Novelty 6/10Timing: after-hours/next-session following the 2026-06-17 Form 4 filing

Background

The article is a SEC Form 4 insider transaction disclosure for NeKTAR Therapeutics (NKTR).

Company-level read

Ticker impact

$NKTRNeutralMedium confidence
Context

NeKTAR Therapeutics disclosed an officer open-market sale: 5,538 shares sold at $60.71 on 2026-06-15 under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any reaction would be sentiment/positioning rather than new fundamentals.

Evidence & confidence

The filing is a routine Form 4 for an officer sale with a pre-arranged 10b5-1 plan; no new operating, clinical, or regulatory facts are provided.

Market effects

Sector

Minimal; this is company-specific insider transaction disclosure without sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can coincide with periods of valuation risk or personal liquidity needs, which some traders may still fade.

Key entities

  • public_company
    NKTR

    NeKTAR Therapeutics; subject of the Form 4 insider sale disclosure.

  • insider
    Zalevsky Jonathan

    Chief R&D Officer who sold 5,538 shares under a pre-arranged 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NKTR insider trading history →

Related articles

OCT 8
$LLYLow

Nektar v. Lilly: Lilly Defeats CRE Claim, But Jury Finds It Owes $90M For Breaching The Implied Covenant Of Good Faith And Fair Dealing

A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.

mondaq.com2 min
OCT 7
$NKTRLow

Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang

Nektar Therapeutics (NKTR) won a $115 million lawsuit against Eli Lilly (LLY), resolving a multi-year overhang. The verdict, including interest, amounts to ~5% of NKTR's market cap. Despite the win, NKTR's stock fell over $200 million in market cap due to market volatility and rising yields. Cedar Grove Capital Management views this as a net positive for NKTR, removing a long-standing uncertainty.

finance.yahoo.com2 min
OCT 1
$NKTRMedAI 8/10

NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge

Nektar Therapeutics (NKTR) shares fell 21% after reporting modest new response rates for its experimental skin drug, rezpegaldesleukin, in alopecia and eczema studies. Despite this, analysts at William Blair and Jefferies maintained bullish ratings, citing the drug's durability advantage. The company also faces an ongoing legal dispute with Eli Lilly.

newsable.asianetnews.com2 min